SEER Inquiry System - Search

Histology/Brain and CNS:  How is histology coded for a 2021 diagnosis of “neuroepithelial tumor with PATZ1-EWSR1 fusion, not elsewhere classified” found during a right thalamic mass resection? See Discussion.

Reportability--Ambiguous Terminology:  Can the term “at most” preceding a statement of a reportable diagnosis be used to accession a case? See Discussion.

First Course Treatment/Cancer-directed Treatment:  What information can registrars use to determine disease progression and whether treatment counts as first course treatment? See Discussion.

Reportability/Histology--Anus:  Are 2021 diagnoses of anal intraepithelial neoplasia (AIN) II or AIN II-III reportable in patients with a known history of AIN II or AIN II-III diagnosed prior to 2021? See Discussion.

Solid Tumor Rules (2018, 2021)/Histology--Cervix:  For cases diagnosed 1/1/2022 and later, how is histology coded for the following three cervix cases relating to p16? See Discussion.

Solid Tumor Rules (2022)/Histology--Bladder:  Can the term configuration be used to code the more specific histology for bladder primaries diagnosed 2022 and later? See Discussion.

Solid Tumor Rules (2018/2021)/Multiple Primaries--Skin Cancer:  How many primaries are assigned for sebaceous carcinomas using the Solid Tumor/Multiple Primaries/Histology Rules?  Does this scenario represent eight separate primaries?  See Discussion.

First Course Therapy/Neoadjuvant Treatment:  How are Neoadjuvant Therapy--Clinical Response and Neoadjuvant Therapy--Treatment Effect coded when the neoadjuvant therapy was not completed? Does the entire course of neoadjuvant therapy need to be completed before we can code these fields? See Discussion.

Reportability/Brain and CNS:  Is a 2021 case of ecchordosis physaliphora (lesion within the prepontine cistern) on brain MRI reportable?

Reportability:  What American College of Radiology Reporting and Data Systems (RADS) can be used to determine reportability?  See Discussion.